Updated data from BeamionLUNG-1, a Phase Ia/b trial of the HER2-specific tyrosine kinase inhibitor, zongertinib(BI 1810631), in patients with HER2 mutation-positive NSCLC

Tuesday, September 24, 2024

Dr. Minal Barve

Read the Story Here

Related Posts

Discover more posts like this.

First-in-human Phase 1/2a Trial of a Macrocyclic ATR inhibitor (ATRN-119) in Patients with Advanced Solid Tumors.

Oct 2, 2024

Dr. Reva Schneider

Results from the first-in-human study of ATR inhibitor, IMP9064 monotherapy dose escalation in patients with advanced solid tumors

Sep 24, 2024

Dr. Reva Schneider

First-in-human results of STX-478, a mutant-selective PI3Kα inhibitor, in advanced solid tumor patients

Sep 24, 2024

Dr. Douglas Orr
See All Posts